Lacosamide

Structural formula
General
Non-proprietary name	Lacosamide
other names	( R ) -2- (Acetylamino) - N -benzyl-3-methoxypropanamide ( IUPAC ); Harkoseride; Erlosamide;
Molecular formula	C 13 H 18 N 2 O 3
External identifiers / databases
EC number	605-756-0
ECHA InfoCard	100.112.805
PubChem	219078
ChemSpider	189902
DrugBank	DB06218
Wikidata	Q420077
Drug information
ATC code	N03 AX18
Drug class	Anti-epileptic
properties
Molar mass	250.29 g · mol -1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS labeling of hazardous substances danger
H and P phrases	H: 301-319
	P: ?
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Lacosamide (trade name: Vimpat ^® ; manufacturer: UCB ) is a drug from the group of anticonvulsants that is used in the treatment of epileptic seizures.

Application areas (indications)

Lacosamide is indicated for monotherapy and additional treatment of partial seizures with or without secondary generalization in adults, adolescents and children from 4 years of age with epilepsy.

Mechanism of action (pharmacodynamics)

The mechanism of action of lacosamide is not fully understood. It is believed that the anticonvulsant effect u. a. is based on an inhibition of voltage-dependent sodium channels . Lacosamide also influences the protein collapsin response mediator protein-2 (CRMP-2). CRMP-2 occurs primarily in the central nervous system and is important for the differentiation of nerve cells and for the sprouting of nerve conduits .

Development history

Lacosamide was synthesized in the 1990s by the US chemist Harold Kohn and later developed by Schwarz Pharma in the areas of epilepsy and pain. After the takeover of Schwarz, the drug was transferred to UCB.

It was first approved as an anticonvulsant in the EU in 2008 . The US health authority FDA had previously rejected an application for approval for the treatment of pain in diabetic polyneuropathy . UCB withdrew a corresponding application for approval for the EU in September 2008.

Web links

Public Assessment Report (EPAR) of the European Medicines Agency (EMA) for: Lacosamide

Individual evidence

↑ Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of (2R) -2- (acetylamino) -3-methoxy-N- (phenylmethyl) propanamide in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on July 6, 2020, is reproduced from a self-classification by the distributor .
↑ SUMMARY OF MEDICINAL PRODUCT CHARACTERISTICS. (PDF) Retrieved June 26, 2019 .
↑ Drug approvals for children. Retrieved June 26, 2019 .
↑ D. Choi, JP Stables, H. Kohn: Synthesis and anticonvulsant activities of N-benzyl-2-acetamidopropionamide derivatives. In: J Med Chem. 39, 1996, pp. 1907-1916. PMID 8627614 .

[1] Template: CL Inventory / not harmonized There is not yet a harmonized classification for this substance . A labeling of (2R) -2- (acetylamino) -3-methoxy-N- (phenylmethyl) propanamide in the Classification and Labeling Inventory of the European Chemicals Agency (ECHA), accessed on July 6, 2020, is reproduced from a self-classification by the distributor .

[2] SUMMARY OF MEDICINAL PRODUCT CHARACTERISTICS. (PDF) Retrieved June 26, 2019 .

[3] Drug approvals for children. Retrieved June 26, 2019 .

[4] D. Choi, JP Stables, H. Kohn: Synthesis and anticonvulsant activities of N-benzyl-2-acetamidopropionamide derivatives. In: J Med Chem. 39, 1996, pp. 1907-1916. PMID 8627614 .